ACTG 5178

ACTG 5178

• 批准号: 7604606
• 负责人: Mark Sebastian Sulkowski
• 金额: $ 8.35万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604606
• 关键词: AIDS clinical trial group; Computer Retrieval of Information on Scientific Projects Database; Detection; Enrollment; Funding; Grant; Hepatitis C virus; Infection; Institution; Label; Liver Fibrosis; Maintenance; Maintenance Therapy; Phase; Rate; Research; Research Personnel; Resources; Ribavirin; Source; United States National Institutes of Health; Upper arm; design; peginterferon alfa-2a

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase II, open-label, two-arm, long-term maintenance therapy study. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿ve and previously treated subjects will be enrolled.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项II期、开放标签、两组、长期维持治疗研究。本试验旨在研究在接受聚乙二醇干扰素α-2a（PEG-IFN）联合利巴韦林治疗期间未能达到或维持HCV载量低于检测限的HCV/HIV合并感染受试者中，长期维持PEG-IFN治疗是否能降低肝纤维化进展率。将入组HCV初治受试者和既往接受过治疗的受试者。